Articles tagged "Survival"

2021 American Transplant Congress
Frailty and Short-Term Outcomes in Kidney Transplant
S. Van Arsdale¹, K. Torbert¹, R. Harland², A. Turner², B. Tanriover³, V. Ariyamuthu³
¹Banner University Medical Center, Tucson, AZ, ²Surgery, Banner University Medical Center, Tucson, AZ, ³Internal Medicine, Banner University Medical Center, Tucson, AZ
*Purpose: Studies suggest worse outcomes for frail solid organ transplant recipients. We analyzed post transplant outcomes in relation to frailty.*Methods: We conducted a retrospective study…
2021 American Transplant Congress
Transplant Center Volume in High-risk Donors are Associated with Graft and Patient Survival
M. A. Merzkani, H. Murad, M. Mattu, M. Wang, V. Hu, S. Chang, T. Alhamad
Transplant, Washington University, Saint Louis, MO
*Purpose: Evaluation of high-risk kidney donors in transplant centers involves an intensive assessment of the individual risks and selection of appropriate recipients. Understandably, this requires…
2021 American Transplant Congress
Living Donor versus Deceased Donor Pediatric Liver Transplantation: A Systematic Review and Meta-Analysis of Outcomes
A. Barbetta¹, C. Butler², S. Barhouma², R. Hogen¹, B. Roque¹, H. Schillperoort³, G. Meeberg⁴, J. Shapiro⁵, Y. Kwon¹, R. Kohli⁶, J. Emamaullee¹
¹Surgery, abdominal transplat, University of Southern California, Los Angeles, CA, ²University of Southern California, Los Angeles, CA, ³Norris Medical Library, University of Southern California, Los Angeles, CA, ⁴Department of Surgery, University of Alberta, Edmonton, AB, Canada, ⁵Department of Surgery,, University of Alberta, Edmonton, AB, Canada, ⁶Department of Pediatrics, University of Southern California, Los Angeles, CA
*Purpose: Reduced size deceased donors and living donor liver transplantation (LDLT) can help address the organ shortage for pediatric liver transplant candidates. Concerns regarding technical…
2021 American Transplant Congress
Renal Transplant Outcomes of Kidney-only vs. Multi-organ Deceased Donors
J. Espinales¹, Z. C. Giffen¹, D. Schneider², R. James³, N. Koizumi³, O. Ekwenna¹, J. Ortiz⁴
¹University of Toledo Medical Center, Toledo, OH, ²UC Irvine School of Medicine, Irvine, CA, ³George Mason University, Arlington, VA, ⁴Albany Medical Center, Albany, NY
*Purpose: We sought to determine the relative outcomes of kidneys from kidney-only or multi-organ deceased donors.*Methods: Scientific Registry of Transplant Recipients data from 2010-2019 were…
2021 American Transplant Congress
20 Year Survival Following Lung Transplantation
R. M. Reul, Jr¹, S. Barrett¹, A. Alnajar², J. Dunson¹, P. S. Garcha³, G. Loor⁴, J. A. Goss⁴, A. A. Rana⁴
¹Office of Student Affairs, Baylor College of Medicine, Houston, TX, ²Department of Surgery, University of Miami Health System, Miami, FL, ³Department of Medicine, Baylor College of Medicine, Houston, TX, ⁴Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX
*Purpose: Outcomes following lung transplantation (LTx) have been poor compared to those of heart, liver, and kidney transplants, with 5-year survival rates around 50%. To…
2021 American Transplant Congress
The Effect of Acuity Circles on Deceased Donor Transplant and Offer Rates Across Meld and Exception Statuses
A. Wey¹, S. Noreen², S. Gentry³, N. Salkowski¹, M. Cafarella², R. Hirose⁴, J. Trotter⁵, D. Segev⁶, A. Israni¹, J. Snyder¹, B. Kasiske¹
¹SRTR, Minneapolis, MN, ²UNOS, Richmond, VA, ³USNA, Annapolis, MD, ⁴Univ of San Francisco, San Francisco, CA, ⁵BSW Health, Dallas, TX, ⁶Johns Hopkins, Baltimore, MD
*Purpose: Acuity circles (AC) allocation was implemented on February 4, 2020. AC significantly changed the relative priority of candidates with allocation PELD/MELD scores of 29…
2021 American Transplant Congress
Patient Survival After Living Donor Kidney Donation
M. G. Naik, K. Sakurayama, K. Budde, F. Halleck
Medical Department, Division of Nephrology and Internal Intensive Care Medicine, Charité, Berlin, Germany
*Purpose: Living donor kidney transplantation [LDKT] is associated with best patient survival and life quality among kidney replacement therapies in case of chronic kidney disease.…
2021 American Transplant Congress
Outcomes After Abo Incompatible Pediatric Liver Transplantation are Comparable to Abo Identical/compatible Transplant
C. Lemoine, K. Brandt, R. Superina
Division of Transplant and Advanced Hepatobiliary Surgery, Ann & Robert H. Lurie Children's Hospital, Northwestern University Feinberg School of Medicine, Chicago, IL
*Purpose: In order to evaluate if the incidence of vascular and biliary complications as well as patient and graft survival in ABO incompatible (ABOi) liver…
2021 American Transplant Congress
Adult Combined Liver-Heart Transplantation: The United States Experience
I. A. Ziogas¹, S. P. Alexopoulos¹, W. K. Wu¹, L. K. Matsuoka¹, M. A. Rauf¹, M. Izzy², R. Perri², K. H. Schlendorf³, J. N. Menachem³, A. S. Shah⁴
¹Division of Hepatobiliary Surgery and Liver Transplantation, Vanderbilt University Medical Center, Nashville, TN, ²Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Center, Nashville, TN, ³Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, ⁴Department of Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN
*Purpose: Combined heart-liver transplantation (CHLT) is now being practiced with increasing regularity and improved outcomes in the United States. We performed the most comprehensive review…
2021 American Transplant Congress
Overall Survival by Best Overall Response with Tabelecleucel in Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant
S. Prockop¹, L. Gamelin², R. Dinavahi², Y. Sun², N. Guzman-Becerra², H. Parmar²
¹Memorial Sloan Kettering Cancer Center, New York, NY, ²Atara Biotherapeutics, South San Francisco, CA
*Purpose: Tabelecleucel is an investigational, off-the-shelf, allogeneic Epstein-Barr virus (EBV)-specific T-cell immunotherapy being studied in patients (pts) with serious EBV-driven diseases, including post-transplant lymphoproliferative disease…